Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 217,564	$ 268,823	$ 285,885
Research and development related success payments and contingent consideration	(8,881)	(48,981)	(84,882)
General and administrative	64,040	73,299	71,561
Total operating expenses	272,723	293,141	272,564
Loss from operations	(272,723)	(293,141)	(272,564)
Interest income, net	10,471	9,938	3,762
Other expense, net	(4,507)	(52)	(674)
Net loss	$ (266,759)	$ (283,255)	$ (269,476)
Net loss per common share - basic	$ (1.16)	$ (1.46)	$ (1.43)
Net loss per common share - diluted	$ (1.16)	$ (1.46)	$ (1.43)
Weighted-average number of common shares - basic	230,891	194,541	188,344
Weighted-average number of common shares - diluted	230,891	194,541	188,344